

Press Release

Systemic Bio, a 3D Systems Company
2450 Holcombe Blvd, Suite 1640-A
Houston, TX, 77021
www.systemic.bio
NYSE:DDD

Investor Contact: investor.relations@3dsystems.com
Media Contact: press@systemic.bio

Systemic Bio to Present Innovative Human-relevant Datasets from h-VIOS™ Platform at SOT and AACR 2024 Annual Meetings

HOUSTON, Texas, February 8, 2024 – [Systemic Bio™](http://www.systemic.bio), a 3D Systems (NYSE:DDD) company, is excited to announce the acceptance of two abstracts for presentation at the prestigious Society of Toxicology (SOT) 2024 Annual Meeting (Salt Lake City, March 10-14, 2024) and American Association for Cancer Research (AACR) 2024 Annual Meeting (San Diego, April 5-10, 2024).

At the SOT 2024 meeting, Systemic Bio will present its latest research on an advanced liver model that demonstrates several-fold enhanced albumin production, CYP (cytochrome P450) activity, and urea production compared to traditional models. This innovative model offers substantial improvements in assessing Drug-Induced Liver Injury (DILI) and Drug Metabolism and Pharmacokinetics (DMPK), marking a significant step forward in liver toxicity testing and drug safety evaluation.

The second abstract, accepted for AACR 2024, showcases a novel model that simultaneously assesses on-target anti-tumor therapeutic efficacy and off-target liver injury of therapeutics across different modalities. This cutting-edge development features connected tissues and is modality-agnostic, allowing for comprehensive evaluation of cancer treatments and their impacts on the liver, a critical aspect in oncology drug development. To delve deeper into this research, all conference attendees and fellow researchers can visit booth #4452 to engage directly with Systemic Bio's team and discover the full potential of the h-VIOS platform.